Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia

Pharmacogenomics

Volumn 15, Issue 7, 2014, Pages 925-932

  Spangaro, Marco ^a   Bosia, Marta ^a,b   Zanoletti, Andrea ^a   Bechi, Margherita ^a   Mariachiara, Buonocore ^a   Pirovano, Adele ^a   Lorenzi, Cristina ^a   Bramanti, Placido ^c   Smeraldi, Enrico ^a   Cavallaro, Roberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SCUOLA UNIVERSITARIA SUPERIORE IUSS PAVIA   (Italy)

^c IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

cognitive impairment; EAAT1; EAAT2; glutamate uptake; schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; FLUPHENAZINE; HALOPERIDOL; OLANZAPINE; RISPERIDONE; THIORIDAZINE; GLUTAMATE TRANSPORTER; SLC1A2 PROTEIN, HUMAN; SLC1A3 PROTEIN, HUMAN;

ADULT; ARTICLE; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA; COGNITIVE DEFECT; CONTINUOUS PERFORMANCE TEST; CONTROLLED STUDY; EAAT1 GENE; EAAT2 GENE; FEMALE; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; N BACK TEST; NEUROPSYCHOLOGICAL TEST; SCHIZOPHRENIA; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; WISCONSIN CARD SORTING TEST; BIOSYNTHESIS; COMPLICATION; GENETICS; MIDDLE AGED; PATHOLOGY;

ADULT; COGNITION DISORDERS; EXCITATORY AMINO ACID TRANSPORTER 1; FEMALE; GENOTYPE; GLUTAMATE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA;

EID: 84903151904     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.42     Document Type: Article

References (26)

1. Javitt DC, Zukin SR, Heresco-Levy U, Umbricht D. Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia. Schizophr. Bull. 38(5), 958-966 (2012).
2. Wang M, Wong AH, Liu F. Interactions between NMDA and dopamine receptors: a potential therapeutic target. Brain Res. 1476, 154-163 (2012).
3. Kim K, Lee SG, Kegelman TP et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J. Cell. Physiol. 226(10), 2484-2493 (2011).
4. Tzingounis AV, Wadiche JI. Glutamate transporters: confining runaway excitation by shaping synaptic transmission. Nat. Rev. Neurosci. 8(12), 935-947 (2007).
5. Spangaro M, Bosia M, Zanoletti A et al. Cognitive dysfunction and glutamate reuptake: effect of EAAT2 polymorphism in schizophrenia. Neurosci. Lett. 522(2), 151-155 (2012).
6. Wang Y, Qin ZH. Molecular and cellular mechanisms of excitotoxic neuronal death. Apoptosis 15(11), 1382-1402 (2010).
7. Shan D, Lucas EK, Drummond JB, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia. Schizophr. Res. 144(1-3), 1-8 (2013).
8. Bauer D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr. Res. 117(1), 92-98 (2010).
9. Ohnuma T, Suzuki T, Arai H. Hypothesis: minimal changes in neural transmission in schizophrenia: decreased glutamatergic and GABAergic functions in the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry. 29(6), 889-894 (2005).
10. Egan MF, Straub RE, Goldberg TE et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc. Natl Acad. Sci. USA 101(34), 12604-12609 (2004).
11. Featherstone RE, Liang Y, Saunders JA, Tatard-Leitman VM, Ehrlichman RS, Siegel SJ. Subchronic ketamine treatment leads to permanent changes in EEG, cognition and the astrocytic glutamate transporter EAAT2 in mice. Neurobiol. Dis. 47(3), 338-346 (2012).
12. Scimemi A, Tian H, Diamond JS. Neuronal transporters regulate glutamate clearance, NMDA receptor activation, and synaptic plasticity in the hippocampus. J. Neurosci. 29(46), 14581-14595 (2009).
13. Mallolas J, Hurtado O, Castellanos M et al. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. J. Exp. Med. 203(3), 711-717 (2006).
14. Poletti S, Radaelli D, Bosia M et al. Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia. Eur. Psychiatry 29(4), 219-225 (2013).
15. Walsh T, McClellan JM, McCarthy SE et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320(5875), 539-543 (2008).
16. Bauer D, Gupta D, Harotunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr. Res. 104(1-3), 108-120 (2008).
17. Karlsson RM, Tanaka K, Heilig M, Holmes A. Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol. Psychiatry 64(9), 810-814 (2008).
18. Karlsson RM, Tanaka K, Saksida LM, Bussey TJ, Heilig M, Holmes A. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 34(6), 1578-1589 (2009).
19. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13(2), 261-276 (1987).
20. Anselmetti S, Poletti S, Ermoli E et al. The brief assessment of cognition in schizophrenia. Normative data for the Italian population. Neurol. Sci. 29(2), 85-92 (2008).
21. Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L. The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci. Biobehav. Rev. 35(3), 573-588 (2011).
22. Bruneau EG, McCullumsmith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Increased expression of glutaminase and glutamine synthetase mRNA in the thalamus in schizophrenia. Schizophr. Res. 75(1), 27-34 (2005).
23. Shan D, Yates S, Roberts RC, McCullumsmith RE. Update on the neurobiology of schizophrenia: a role for extracellular microdomains. Minerva Psichiatr. 53(3), 233-249 (2012).
24. Fumagalli E, Funicello M, Rauen T, Gobbi M, Mennini T. Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1. Eur. J. Pharmacol. 578(2-3), 171-176 (2008).
25. Beller JA, Gurkoff GG, Berman RF, Lyeth BG. Pharmacological enhancement of glutamate transport reduces excitotoxicity in vitro. Restor. Neurol. Neurosci. 29(5), 331-346 (2011).
26. Huerta I, McCullumsmith RE, Haroutunian V, Giménez-Amaya JM, Meador-Woodruff JH. Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia. Synapse 59(7), 394-402 (2006).